PARTICIPANT LIST

Albanese, Alberto,. Istituto di Neurologia, Universita Cattolica, Largo A. Gemelli, 8, 00168 Rom~, Italy

Ansell, G. Brian, Department of Pharmacology, University of Birmingham, The Medical School, Birmingham B15 2TJ, UK

Aquilonius, Sten-Magnus, Department of Neurology, University Hospital, S-750 14 Uppsala, Sweden

Barker, Louis A., Department of Pharmacology, The Mount Sip.ai Medical Center, New York, New York, 10029 USA

Bartfai, Tamas, Department of Biochemistry, Arrhenius Laboratory, University of Stockholm, S-1069l, Stockholm, Sweden

Bartolini, Alessandro, Department of Pharmacology, University of Florence, 50134, Florence, Italy

Beani, Lorenzo, Department of Pharmacology, School of Medicine, University of Ferrara, 44100 Ferrara, Italy

Bianchi, Beani, Clety, Department of Pharmacology, School of Pharmacy, University of Ferrara, 44100 Ferrara, Italy

Bigl, Volker, Abteilung fur Neurochemie, Karl Mark Universita t, Karl-Marx-Stadter Str. 50, DDR-7039 Leipzig, Germany

Birdsall, Nigel, J .M., National Institute for Medical Res·earch, The Ridgeway, Mill Hill, London NW? 1AA, UK

Bisso, Guillermo Mario, Laboratorio di Fa,rmacologia, :R,ep. Farmacologia Biochimica, Istituto Superi.ore di Sanita, Viale Regina Elena 299, Rome, Italy

Blass, John, Burke Rehabilitation Center, 385 Mammaroneck Avenue, White Plains, New York 10605, USA

963

964

Bonetti, Anna Chiara, Fidia Research Labora.tories, 35031 Abano Terme, Italy

PARTICIPANTS LIST

Butcher, Larry L., Department of Psychology and The Brain Research Institute, University of California, Los Angeles, California 90024, USA

Ca1derini, Gabriella, Fidia Research Laboratories, 35031 Abano Terme, Italy

Carmignoto, Giorgio, Fidia Research Laboratories, 35031 Abano Terme, Italy

Casamenti, Fiorella, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Ceccarelli, Bruno, Department of Pharmacology, University o£, Milan, 20129 Milan, Italy

Cheney, Darwin L., Laboratory of Preclinical Pharmacology, NIMH, St. Elizabeth's Hospital, Wa.shington, D.C. 20032, USA

Collier, Brian, Department of Pharmacology, McIntyre Medical Sciences Bldg., McGill University, Quebec H3G lYo, Canada

Consolo Ladinksy, Silvana, Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy

Cooper, Jack R., Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510 USA

Corradetti, Renato, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Corthay, Jacqueline, Department of Pharmacology, 20 rue de l' E.co1e de Medicine, 1211 Geneva 4, Switzerland

Costa, Erminio, Laboratory of Preclinical Pharmacology, NIMH, St. Elizabeth's Hospital, Washington, D.C. 20032, USA

Dahlbom, Richard, Department of Pharmaceutical Chemistry, University of Uppsa1a, S-750 Uppsala, Sweden

Davis, Kenneth, Bronx Veteran's ADministra.tion Hospital, Bronx, New York 10468 USA

De Biasi, Silvia, Fidia Research Laboratori.es, 35031 Aliano Terme, Italy

PARTICIPANTS LIST

DiGiamberardino, Luigi, CEA de Sac1ay~DB/LLPC, Boite Posta1e 2, 91190 Gif-sur-Yvette, France

Dimpfe1, W., Fidia Research Laboratories, 35031 Abano Te.rm.e, Italy

Domino, Edward F., Department of Pharmacology, University of Michigan, Medical School, Ann Arbor, Michigan 45105 USA

Dowdall, Michael J., Department of Biochemistry, The Medical School, University of Nottingham, Nottingham, UK

965

Dun, Nae J., Department of Pharmacology, Loyola University Stritch School of Medicine, 2160 S. First Avenue, Maywood, Illinois 60153 USA

Dunant, Yves, Department of Pharmacology, 20 rue de 1tEco1e de Medecine, 1211 Geneva 4, Switzerland

Eckernas, Sven-Ake, Department of Neurology, University Hospital, S-750 14 Uppsa1a, Sweden

Fesce, R., Department of Pharmacology, University of Milan, 20129 Milan, Italy

Ferrari, Giovanna, Fidia Research Laboratories, 35031 Abano TeJ;"me, Italy

Fibiger, Hans C., University of British Columbia, Department of Psychiatry, Vancouver V6T 1W5, Canada

Filogamo, Guido, Istituto di. Anatomia Umana Norma1e, University of Torino 10126 Torino, Italy

Flentge, F., Department of Biological Psychiatry, Academisch Ziekenhuis Groningen, 9700 RB Groningen, The Netherlands

Fonnum, Frode, Department of Toxicology, Norwegian Def:ence Research Establishment, N-2007, Kje11er, Norway

Froissart, Chantal, Certre de Neurochemie du CNRS, 11 rue Humann 67085 Strasbourg cedex, France

Fu1pius, Bernard W., University of Geneva, Department of Bio­chemistry, Sciences II, 1211 Geneva, Switzerland

Galli, Alessandro, Department of Pharmacology, School of: Medicine, University of Florence 50134, Florence, Italy

Giacobini, Ezio, Department of Biobehaviora1 Sciences U~154, University of Connecticut, Storrs, Connecticut 0626.8 USA

966 PARTICIPANTS LIST

Gibson, Gary, Department of Neurology, Cornell Medical College, Burke Rehabilitation Center, 785 Mamaroneck Avenue, White Plains, New York, 10605 USA

Gillin, J. Christian, National Institute of Mental llealth, NIH, Bethesda, Maryland 20205 USA

Gorio, Alfredo, Fidia Research Laboratories, 35031 Abano Terme, Italy

Han in , Israel, University of Pittsburgh, School of Medicine, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, Pennsylvania 15261 USA

Haubrich, Dean R., Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486 USA

Hedlund, Britta, Department of Biochemistry, Arrhenius Laboratory, University of Stockholm, S-1069l Stockholm, Sweden

Heilbronn, Edith, Unit of Neurochemistry and Neurotoxicology, University of Stockholm, c/o FOA Ursvik, S-104 SO Stockholm, Sweden

Hemsworth, Brain A., University of Aston, Department of Pharmacy, Gosta Green, Birmingham, B4 7ET, UK

Hersh, Louis B., Department of Biochemistry, The University of Texas, Health Science Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235 USA

Hopff, Wolfgang, Department of Pharmacology, University of Zurich, Gloriastasse 32, CH-8005, Zurich, Switzerland

Howard, Bruce, Department of Biological Chemistry, School of Medicine, University of California, Los Angeles, California 90024 USA

Israel, Maurice, CNRS, Laboratory of Cellular Neurobiology, Department of Neurochemistry, 91190 Gif-sur-Yvette, France

Jenden, Donald J., Department of Pharmacology, School of Medicine, University of California, Los Angeles, California 90024 USA

Jape, Richard S., Department of Pharmacology, School of Medicine University of California, Los Angeles, California 90Q24 USA

Karczmar, Alexander, G., Loyola University Stritch School of Medicine, Department of Pharmacology, Maywood, Illi.nois 60153 USA

PARTICIPANTS LIST

Kewitz, K., Freie Universitat Berlin, Institut fur Klinische Pharmakologie, Hindenburgdamm 30, D-1000 Berlin 45 Germany

967

Kharkevich, Dimitry A., Department of Pharmacology, First Medical Institute, 2/6 B. Pirogovskaja St., Moscow 1194R'} TJSSR

Kilbinger, Heinz, Department of Pharmacology, University of Mainz, D-6500 Mainz, Germany

Kimura, Hirosh, Kinsman Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, Canada

Koelle, George B., Department of Pharmacology, School of Medicine University of Pennsylvania, Philadelphis, Pennsylvania 19174 USA

Koenig, Herbert, Universite P. et M. Curie, Laboratoire de Neuro­cytologie, 7 Quai St. Bernard, Bat A/3c, 75005 Paris, France

Lotas, A.M., Department of Pharmacology, Univesrity of London, Kings College, The Strand, London WC2R 2LS, UK

Kuhar, Michael J., Department of Pharmacology, John Hopkins University, School of Medicine, 725 N. Wolfe Street, Balti­more, Maryland 21205 USA

Ladinsky, Herbert, Mario Negri Institute of Pharmacological Research, 20157 Milan, Italy

Leon, Alberta, Fidia Research Laboratories, 35031 Abano Terme, Italy

Lo Conte, Giovanni, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Loffelholz, Konrad, Department of Pharmacology, University of Mainz, Obere Zahlbacher Strasse 67, 6500 Mainz, Germany

Longo, Vincenzo, Istituto Superiore di Sanita, Viale Regina Elena 299, 00100 Rome, Italy

Lowenadler, Bjorn, Department of Neurochemistry and Neurotoxicology, University of Stockholm, c.o FOA Ursvik, S-104 50 Stockholm, Sweden

Lqumani, Yunas A., Max-Planck-Institut, Biophysical Chemistry, Postfach 968, Gottingen, Germany

M.-~ 1mb erg , Aiello, Petra, Department of Pharmacology, University of Florence, 50134 Florence, Italy

968 PARTICIPANTS LIST

Ma1the-Sorenssen, Didrik, Division of Toxicology, Norwegian Defence Research Establishment, N-2007 Kje11er, Norway

Manaranche, M., CNRS, Laboratory of Cellular Neurobiology, Depart­ment of Neurochemistry, 91190 Gif-sur-Yvette, France

Mantovani, Piero, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Marchbanks, Roger M., Department of Biochemistry, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK

Marchi, Mario, Department of Biobaviora1 Sciences U-154, University of Connecticut, Storrs, Connecticut 06268 USA

Massare11i, Raffaele, CNRS, Center of Neurochemistry, 11 rue Humann. 67085 Strasbourg cedex, France

Mautner, Henry G., Department of Biochemistry and Pharmacology, School of Medicine, Tufts University, 136 Harrison Avenue, Boston, Massachusetts 02111 USA

Michalek, Moricca Hanna, Laboratorio di Farmaco1ogia, Rep. Farma­co1ogia biochimica, Instituto Superiore di Sanita, Via1e Regina Elena 299, 00100 Rome, Italy

Mittag, Tom, Pharmacology Department, Mt. Sinai School of Medicine, One Gustave Levy Place, New York, New York 10Q29 USA

Molenaar, Peter C., Department of Pharmacology, Sy1vius Laboratories, University of Leiden, 72 Wassenaarseweg, Leiden, The Netherlands

Moroni, F1avio, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Neal, J., Department of Pharmacology, School of Pharmacy, 29 Brunswick Square, London we1, UK

Nordberg, Agneta, Department of Pharmacology, University of Uppsa1a, Box 578, 75123 Uppsa1a, Sweden

Oderfe1d-Nowak, Barbara, Institute of Experimental Biology, Polish Academy of Sciences, Pasteur 8, 02093 Warsaw, Poland

Paggi, Paola, Institute of General Physiology, University of Rome, 00100 Rome, Italy

Pauling, Peter, Chemistry Department, University College London, 20 Gordon Street. London UCI. UK

PARTICIPANTS LIST 969

Pedata, Felicita, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Pedigo, Norman W., Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona 85724 USA

Pepeu, Giancarlo, Department of Pharmacology, School of Medicine, University of Florence, 50134 Florence, Italy

Perri, Virgilio, Institute of General Physiology, University of Ferrara, Via L. Borsari 46, 44100 Ferrara, Italy

Piazza Bartolini, Roselia, Department of Pharmacology, University of Florence, 50134 Florence, Italy

Polak, Robert, Medical Biology Laboratories, TNO, Ryswyk, The Netherlands

Procellati, Giuseepe, Institute of Chemical Biology, University of Perugia, 06100 Perugia, Italy

Prince, Alan Keith, Department of Pharmacology, University of London, Kings College, The Strand, London WC2R 2LS, UK

Racagni, Giorgio, Institute of Pharmacology and Pharmacognosia, University of Milan, 20129 Milan, Italy

Reynolds, R., Department of Pharmacology, Univesrity of London, Kings College, The Strand, London WC2R 2LS, UK

Renzi, Giovanni, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Florence, 50121 Florence, Italy

Richardson, G. Peter, Max-Planck-Institut, Biophysical Chemistry, Postfach 968, 34 Gottingen, Germany

Riggio, G., Department of Pharmacology, University of Zurich, Gloriastrasse 32, CH-8006 Zurich, Switzerland

Robinson, Susan, Department of Pharmacology, College of Medicine, Texas A&M University, College Station, Texas 77843, USA

Scatton, Bernard, Synthelabo-LERS, 31 Avenue Paul-Vaillant Coutorier, 92220 Bagneux, France

Siniscalchi, Rossi, Anna, Department of Pharmacology, School of Medicine, University of Ferrara, 44100 Ferrara, Italy

Sitaram, Nastrai, National Institute of Mental Health, NIH, Bldg. 10, Room 3N224, Bethesda, Haryland 20014, USA

970 PARTICIPANTS LIST

Sorbi, Sandro, Neurol.ogical Clinic, School of Medicine, University of Florence, 50134 Florence, Italy

Spanner, Sheila, Go, Department of Pharmacology, The Medical School, University of Birmingham, Birmingham B15 2TJ, UK

Stadler, Herbert, Max-Planck-Institut, Biophysical Chemistry, Postfach 968, 34 Gottingen, Germany

Stavinoha, William Bo, The University of Texas Medical School, Department of Pharmacology, San Antonio, Texas, 78284, USA

Suszkiw, Janus Bo, The Biological Sciences Group, The University of Connecticut, Storrs, Connecticut, 06268 USA

Szerb, John Co, Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, B3H 4H7 Canada

Tanganelli, Sergio, Department of Pharmacology, University of Ferrara, 44100 Ferrara, Italy

Teolato, Sandra, Fidia Research Laboratories, 85031 Abano Terme, Italy

Tirelli, Silvia, Mario Negro Institute of Pharmacological Research, Via Eritrea 62, Milan, Italy

Toffano, Gino, Fidia Research Laboratories, 35031 Abano Terme, Italy

Toschi, Go, Institute of General Physiology, University of Rome, 00100 Rome, Italy

Tucek, Stanislav, Academy of Sciences, Insitute of Physiology, Videnska 1083, 14220 Prague, Czechoslovakia

Ulas, Jolanta, Nencki Institute of Experimental Biology, 3 Pasteur Strasse, 02093 Warsaw, Poland

Vizi, Sylvester, Department of Pharmacology, Semmelweis University of Medicine, H-1445 Budapest, Hungary

Wachtler, Klaus, Institut fur Zoologie, Der Tierartlishen Hoch­schule, 3 Hannover, Germany

Wahlstrom, Goran, University of Umea, Department of Pharmacology, S-90l,87 Umea, Sweden

Wecker, Lynn, Department of Pharmacology, Louisiana State University Medical Center, New Orleans, Louisiana 70112 USA

PARTICIPANTS LIST 971

Weiler, Molly, Laboratory for Neurochemistry, Max-Planck-Institut for Biophysical Chemistry, D-3400 Gottingen, Germany

Wenk, Hartmut, Abt. Neurochemie, Paul F1echsig Institut Hirnfor­schung, Karl Marx Stadtea Strasse 50, DDR-7039, Leipzig, Germany

Wessler, Ignaz, Department of Pharmacology, University of Mainz, D-6500, Mainz, Germany

Whittaker, Victor P., Laboratory for Neurochemistry, Max-Planck­Institut for Biophysical Chemistry, D-3400 Gottingen, Germany

Wong, Tuen Yee, CNRS, Center for Neurochemistry, rue Humann, 67085 Strasbourg cedex, France

Wood, Paul L., Department of Pharmacology, Merck Frosst Laboratories, P.O. Box 1005, Pointe Claire-Dorval, Quebec H9R 4p8 Canada

Zimmerman, Herbert, Laboratory for Neurochemistry, Max-Planck­Institute for Biophysical Chemistry, D-3400 Gottingen, Germany

Zsi11a, G., Department of Pharmacology, Semmelweis University of Medicine, H-1445 Budapest, Hungary

CONTRIBUTOR INDEX

Albanese, A., 723 Aloisi, F., 833 Ansell, G.B., 393 Aprison, M.H., 739 Aquilonius, S.M., 871, 879 Bak, 1.J., 531 Barker, L.A., 475 Bartfai, T., 579 Bartholini, G., 771 Battistella, A., 601 Beani, L., 763 Belluzzi, 0., 119 Berrie, C.P., 595 Bianchi, C., 763 Biesold, D., 673 Bigl, V., 673 Biondi, C., 119 Birdsall, N.J.M., 587, 595 Bisso, G.M., 847 Blass, J.P., 921 Blendy, J., 947 Bolzoni, L., 153 Bonetti, A.C., 601 Borasio, P.G., 119 Burgen, A.S.V., 595 Butcher, L.L., 723 Butcher, S.H., 723 Brunetti, M., 377 Calderini, G., 601 Capuzzo, A., 119 Carmignoto, G., 221 Casamenti, F., 685 Cheney, D.L., 705, 715, 825 Collier, B., 97 Consolo, S., 781 Cooper, J.R., 521 Corthay, J., 287, 321

973

Costa, E., 143, 705, 715, 825 Couraud, J.Y., 387 Cuenoud, S., 333 Dahlbom, R., 621 Davis, B.M., 929 Davis, K.L., 929 Davis, R., 127 Demetriou, S.K., 891 DeNigris, Y., 929 Dewey, W.L., 795 di Giamberardino, L., 377, 387 Dolezal, V., 415 Domino, E.F., 891 Dowdall, M.J., 249 Dowe, G.H.C., 235 Droz, B., 377 Duffy, T.E., 443, 921 Dun, N.J., 109 Dunant, Y., 287, 321 Eckernas, S.A., 871, 879 Eder, L., 287 Ehlert, F.J., 609 Ferretti, M.E., 119 Fibiger, H.C., 663 Filogamo, G., 85 Finesso, M., 221 Fonnum, F., 569 Forloni, G.L., 781 Fretten, P., 249 Froissart, C., 91 Fucek, F., 8'91 Fulpius,.B.W.,333 Garelli, M., 659 Gerber, N.H., 425 Gershon, E.S., 947 Giacobini, E., 1, 25 Giacobini-Robecchi, M.G., 659

974

Gibson, G.E., 443, 921 Gillin, J.C., 937, 947 Giompres, P., 261, 301 Goldberg, A.M., 451 Gorio, A., 221 Guidotti, A., 143 Hammar, R., 595 Hanbauer, I., 143 Han in , I., 901, 937 !iartvig, P., 879 Haubrich, D.R., 425 Hedlund, B., 579, 647 Hei1bronn, E., 343 Hexum, T., 143 Himme1hoch, J.M., 901 Hofmann, A.A., 323 Hopff, W .H., 323 Horvath, T.H., 929 Howard, B.D., 133 Hulme, E.C., 595 Israel, M., 215, 273 Jenden, D.J., 497, 531 Jope, R.S., 497 Jumblatt, J.E., 367 Kalaria, R.N., 73 Karczmar, A.G •• 109, 853 Kewitz, H., 405 Kharkevich. D.A .• 351 Kilbinger, H., 169, 235 Kumura, H., 695 Koelle, G.B., 127 Koelle, W.A., 127 Koenig, H.L., 377 Koff, U., 901 Kotas, A.M., 73, 469 Krammer, C., 937 Kr enz, W. D., 47 Kruel, R., 169 Ksiezak, H.J., 443 Kuhar, M.J., 587 Kupfer, D.J., 901 Ladinsky, H., 781 Larsson, C., 639 Lefvert, A.K., 333 Lehmann, J., 663 Leon, A., 221 Lindmar, R., 159 Lindstrom, B., 879 Lo Conte, G., 685

CONTRIBUTOR INDEX

Loctin, F., 287, 321 Loffelholz, K., 159 Longo, V.G., 833 Lowenadler, B., 343 Luqmani, Y.A., 301, 307 Lund-Karlsen, R., 569 Mallinger, A.G., 901 Manaranche, R., 215 Marchbanks, R.M., 489 Marchi, M., 1, 25 Marini, P., 221 Marquis, J.K., 367 Massarelli, R., 91, 511 Massey, S.C., 555 Mathews, B., 891 Mautner, H.G., 367 McGeer, E.G., 695 McGeer, P.L., 695 Melega, W.P., 133 Meneguz, A., 153, 847 Meyer, E.M., 521 Meyer, U., 673 Michalek, H., 847 Miledi, R., 197, 205 Misgeld, U., 531 Mittag, T.W., 541 Mohs, R.C., 929 Milenaar, P.C., 197, 205 Moore, A.M., 947 Neal, M.J., 555 Neil, J.F., 901 Nordberg, A., 639, 809, 819 Nordstrom, 0., 579 Nurnberger, J.I. Jr., 847 Oderfeld-Nowak, B., 739 Opsahl, M., 569 Opstad, P.K., 569 o t Regan, S., 97 Osterman, P.O., 879 Paggi, P., 153 Pedata, F., 685 Pedigo, N.W., 795 Peng, J.H., 695 Pepeu, G., 685 Perri, V., 119 Pflueger, A.B., 425 P1eul, 0., 405 Plum, F., 921 Polak, R.L., 197, 205

CONTRIBUTOR INDEX

Porcellati, G., 377 Pouch, W.P., 425 Prince, A.K., 73, 463, 469 Revuelta, A.V., 825 Reynolds, R., 73, 463 Richard, K.K., 127 Ricny, J., 415 Riggio, G., 323 Robinson, S.E., 705 Roeske, W.R., 609 Rosenberg, G.S., 929 Ruch, G.A., 127 Saiani, 1., 143 Samoilov, D.N., 351 Sanville, U.J., 127 Scotti de Carolis, A., 833 Scatton, B., 771 Segal, M., 781 Shorr, V.A., 351 Sisto-Daneo, L., 85 Sitaram, N., 937., 947 Skoldinov, A.P., 351 Soli, N.E., 569 Sorbi, S., 685 Spanner, S.G., 393 Spiker, D.G., 901 Stadler, R., 241 Stalberg, E., 879 Stockton, J., 595 Suszkiw, J.B., 313 Szerb, J.C., 177 Ta it, S. K., 891 Tanganelli,zS., 763 Tashiro, T., 47 Teolato, S., 601

Thieffry, M., 215 Tirelli, A.S., 781 Toffano, G., 601 Toyka, K., 343 Tredese, L., 221 Trevisani, A., 119 Tucek, S., 415 Uden, A., 579 Ulas, J., 841 Vanskiver, C., 947 Vizi, E.S., 187 Wachtler, V.P., 4, 47, 59 Wahlstrom, G., 809, 819 Walker, J. H., 653 Wamsley, J.K., 587 Waser, P.G., 323 Wecker, L., 451 Weide, W., 159 Weiler, M.H., 531 Weingartner, H., 937 Wenk. H., 673 Wessler, l. 169 Westlind, A., 579

975

Whittaker, V.P., 47,235,261,307 Witzmann, V., 47, 653 Wojcik, M., 841 Wong, P.T.H., 73 Wong, T.Y., 511 Wood, P.L., 715 Woolf, N.J., 723 Yamamura, H.I., 609 Yang, H.Y.T., 143 Zanoni, R., 221 Zarbin, M.A., 587 Zimmermann, H., 261

SUBJECT INDEX

A23187 on ACh release, 523,580

Abstinence after barbital, 819

Acetate in ACh synthesis, 262,314,415

N-Acety1ated amino acids, 415 Acety1carnitine

and acetate incorporation, 314 in ACh synthesis; 416

Acetyl CoA endogenous source, 503 from acety1carnitine, 314 from citrate, 415 from glucose, 416,490 from pyruvate, 415,501 in ACh synthesis, 415

Acetyl group source of, 415

Acetyl-8-methylcholine, 549,613 Acetyltriethylcholine, 309 Acetylmonoethylcholine, 274 ACh

and antinociception, 796 and binding, 613 and high affinity transport, 475 assays for, 715,782 bound, 276,291 cytoplasmic, 294,490 free, 294 in brain through phylogeny, 62 in neuronal cultures, 516 in sympathetic and para-

sympathetic ganglia, 9 interactions, 875 in the cornea, 542 in the retina, 543 in the striatum, 734 labile bound, stabile bound, 507 level and barbital, 811

and GABAergic drugs, 771 and neuropeptides, 715 and oxotremorine, 782 in brain, 715,771,782 in caudate slices, 421 in chronic barbital treat­

ment, 809

977

in hippocampus, 716,782 in mammalian skeletal

muscle, 2Q5 metabolism and ~ depolariza-

tion, 531 regulation of synthesis, 97 source of, 410 storage, 261.273 synthesis

and choline transport, 489,49~ and glucose, 421,922 and hypoxia, 443 in cholinergic nerve

nerve terminals, 97 in isolated heart, 159

ACh release A23l87 on, 580 4-aminopyridine on, 293 and choline transport, 489 and Na-K ATPase, 187,521 atropine on! 169,184,580 black widow spider venom on, 224 Ca++ on, 184, 188 carbachol on, 292,580 cations on, 188 p-chloromercuribenzoate on, 188 chloropromazine on, 188 choline on, 174,455 C1- on, 458 DFP on, 292 digoxin on, 188 electrical stimulation on,

169, 766 ethanol on, 188 N-ethy1male.imide on, 188 from central neurons, 169 from diaphragm, 455 from electric organ, 288 from hippocampal slices, 580 from isolated heart, 159 from myenteric plexus, 169. 177 from Schwann cells, 223 from superior cervical

ganglia, 455 from synaptosomes, 489,504,

521,579 from the retina, 555

978

GABA ont 763 K+ on, 169,187,580,766 mechanism of, 283 Mn++ on, 183 naloxone on, 184 nicotinic drugs on, 169 non quantal, 187,209 noradrenaline on, 526 ouabaine on, 187,224,293,580 oxotremorine on, 184, 580 quantal, 187,192,216 quinidine on, 188 regulation of, 224 scopolamine on, 170 tetrodotoxin on, 580 veratridine on, 580 vesicular, 307

ACh turnover and 69 tetrahydro­

cannabino1s, 826 and oxotremorine, 782 during development, during

aging, 18,42 effect of drugs on, 715,874 in ganglia, 100 in hippocampus, 708,716,782 in PC12 cells, 138 vesicular, 506

ACh uptake, 301 AChE

after lesion of the n. basalis magnoce11u1aris, 667

and chronic barbital, 813 distribution in the brain, 723 -dopaminergic re1ationships,725 effect of 5-HT on, 741 from bovine red blood cells,750 in brain through phylogeny, 62 in cortical areas, 674 in denervated iris, 549 in denervated muscle, 387 in developing electric organ,50 in frog skeletal muscle, 197 inhibition of the iris, 569 inhibitors, 170, 325, 329, 402,

420,453,879,948 in hippocampus, 842 in neural crest, 2 in superior cervical gang1ion,128

SUBJECT INDEX

in thyroid deficiency, 78 molecular forms of, 847 separation from AChR, 325 staining for, 127,664 vesicular, 264

AChR see ACh receptors

ACh receptors see J;Iluscarinic see nicotinic

Adamantyl radical, 359 Adenosine

in nerve ending, 295 on ACh release, 293

Adrenal medulla enkephalins in, 144

Adrenoceptors, 784 Aging

of cholinergic synapse, 27 similarity with axotomy, 33

Alternation, spontaneous, 604 Alzheimer's disease, 929 Amino acids

in AChR, 329 2-Amino-2-methy1propanol

(2-AMP), 434 4-Aminopyridine

and ACh release, 293,874 and giant epp, 291 and norepinephrine turnover,874 binding to axonal membranes,372 in Eaton Lambert syndrome, 874 in Huntington's chorea, 871

Amphetamine effect on

ACh output, 688 ACh turnover in the

hippocampus, 710 on striatal ACh level, 734

Amphibia brain cholinergic

mechanisms in, 65 Analgesia

cholinergic, 860 Anatruxonium, 356 Antibody

against ACh receptors,333,343 Anticholinergic drugs

structure action relationship,351

SUBJECT INDEX

Antihistaminic, 362 Antimycin A, 448 Antinociception

and cholinomimetic drugs,795,833 and narcotic analgesics, 795 and procaine, 833 chelating agents on, 796 divalent cations on, 796 tests for, 796,833

ADAA, 606 Arecoline

and cortical arousal, 949 and dreaming, 949 the first REM period, 949 antinociceptive activity,795,835 in Huntington's chorea, 875

Apomorphine, 733 on ACh turnover in

hippocampus, 708 Ataxia

choline trials in, 873 ATP

-citrate lyase, 418 content in vesicles, 242 in vesicles,z26l

ATPase, 187,521 Atropine, 169, 357, 604, 833

and chronic barbital, 819 and QNB binding sites, 547 binding, 613

to axonal membranes, 372 effect on ACh release, 184,580 in myasthenia gravis, 336 in the brain, 589 in the eye, 547 on brain ACh, 453,783 on choline-induced increase

in homovanillic acid, 433 on striatal ACh, 734

Autoreceptors, 579 Axoaxonic synapse, 716,786 Axonal

membranes, 367 sprouting, 221 transport,

of AChE and BuChE, 389 of cholinephospho­

glycerides, 377 Axotomy

and motor nerve sprouting, 221

changes in ganglionic synapses, 33

Azide on choline uptake, 135

Barbital

979

chronic treatment, 809,819 Betaine, 433,514 Bicuculline, 561,716,766

intraseptal, 708,827 Bird

brain cholinergic mechanisms in, 65

embryos, 85 Binding studies

see muscarinic receptor see nicotinic receptor

Bis-(thioacetoxy)aurate, 127 Black widow spider, 153,224 Brain nuclei

muscarinic receptor distribution in, 589

Broca's diagonal band nucleus, 676

3-Bromopyruvate, 420,480 BuChE

as a precursor of AChE, 130 in denervated iris, 549 in denervated muscle, 389 in superior cervical

ganglion, 128 S-Bungarotoxin (S-Btx), 249

and receptor isolation, 656 binding

in the brain, 640 sites, 343

changes with age, 34 development of, 11

effect on, 12 in adrenals, 151 in myasthenia gravis,334 in the eye, 544 on ACh release in

Torpedo, 292 with horseradish

peroxidase, 369 in denervated skeletal

muscle, 659

980

to axonal membranes, 369

Ca++ and antinociception, 803 and muscarinic receptors, 649 channel, 224 clearance, 273 D-pOO, 218 efflux, 525 -free solution, 523,557 on ACh release, 183,188,310 on choline uptake, 99 on GPC diesterase, 400 uptake, 277

cAMP, 601 in ganglia, 121,123

Cannabidiol, 826 Cannabis sativa, 826 Carbachol, 292,360,591,597,833

on ACh release, 580 Carbamylcholine, 368,549

and binding, 612 in myasthenia gravis, 336

Carbohydrates in AChR, 329

8-Carbolines on cholinergic mechanisms, 745

Carnitineacetyltransferase, 212 CAT

see cholineacetyltransferase Cations

on nociception, 796 Caudate nucleus

ACh level in, 773 choline level in, 773 GPC diesterase in, 398 -putamen complex, AChE in, 731 slices, ACh, acetyl-CoA,

choline levels in, 421 Cerebellum

and cAMP and cGMP levels, 604 nicotinic binding sites in, 643 through phylogeny, 70

cGMP, 601 Ch

see choline ChAr

see cholineacetyltransferase Chlorisondamine

effect on development, 12

SUBJECT INDEX

p-Chloromercuribenzene sulphonate, 523

p-Chloromercuribenzoate on ACh release, 188

p-Chlorophenylalanine, 798 4-Chloro-7-nitrobenzenfurazon

(NBD-Cl), 139 Chlorpromazine

on ACh release, 188 Cholesterol

in synaptic vesicles, 242 Choline

absorption of, 438 after lecithin, 943 and base exchange, 381 and chronic barbital, 821 and lithium therapy, 891 phospholipid synthesis, 378,385 arterovenous difference, 405 assay for, 894 blood cell level, 897 brain turnover rate, 412 deficient diet and

brain ACh, 452 effect on acetyl-CoA, 420

on ACh level, 420,453 on ACh synthesis, 162,317,

425,535 on dopamine synthesis, 413

free pool of, 503 from phospholipids, 495 hippocampal level, 788 in blood, 901 in clinical trials, 873 in the striatum, 734 level in chronic barbital

treatment, 809 low affinity transport, 893 metabolism

in guinea pig, 435 in rat, 435

on ACh release, 174 on brain cAMP, 601 on brain cGMP, 601 on muscarinic receptQrs.174, 874 plasma levels, 897 RBC/plasma ratio, 891 source of, 385,393,405 synthesis in brain, 393,405

SUBJECT INDEX

Cho1ineacety1transferase, 402,772 after lesion of the n. basalis

magnoce11u1aris, 666,675 and ACh synthesis, 426 and choline uptake, 482 distribution in the brain, 723 immunoreactive staining, 700 in brain through phylogeny, 62 in chronic barbital treatment,809 in ciliary ganglion, 4 in developing electric organ, 50 in hippocampus, 842 in human placenta, 91 in inbred strains of mice, 474 in skeletal muscle, 205 in the eye, 543 in thyroid deficiency, 78

Choline analogs, 475 and electrostatic potentials,475 and free hydroxyl group, 475 on ACh synthesis, 434 uptake, 99,274,308

Choline deficient diet, 452 Choline dehydrogenase, 435 Choline efflux, 493,504,534 Choline kinase

and hemicholinium-3, 401 Choline phospho glycerides

as source of choline, 377,385 axonal transport of, 377 synthesis in perikarya, 377

Choline transport and acetylation, 501 and ACh synthesis, 491,497 neuraminidase on, 518

Choline therapy in neurological disorders, 873

Choline uptake and ACh release, 458 and ACh synthesis, 456 and choline analogs, 97 and depolarization, 493 development in ciliary

ganglia, 3,14 effect of C1- on, 456

of oxotremorine on, 782 high affinity, 456,475 in aging synapses, 35 in chronic barbital

treatment, 809

981

in inbred strains of mice, 463 in nerve cultures, 511 in PC12 cells, 134 in sympathetic ganglia, 101 in thyroid deficiency, 78 kinetics of, 469,498,517 low affinity, 456

Cholinergic-adrenergic balance hypothesis in depression and mania, 948 Cholinergic agents see also cholinomimetics use of, 853

Cholinergic mechanisms chronic barbital on, 809 effect of S carbolines on,745 in pupillary diameter, 949 in REM sleep, 949 in temperature regulation,949

Cholinergic-monoaminergic interactions, 723,781

Cholinergic pathways, 671,680, 715,777 ,786 septal-hippocampal, 705

Cholinergic systems anatomical organization of,663 in memory and learning, 859 mapping of, 695

Cholinomimetic agents and antinociceptive

activity, 795 and human memory, 929 and nociception, 833 and sleep studies, 949 and spontaneous alternation,604 in primary effective il1ness,947

Chromaffin cells, 145 Ciliary body, 543 Ciliary ganglion, 377 Cingulum, 718 Cirraso1, 325 Citrate

in ACh synthesis, 415 Citric acid cycle

and ACh synthesis, 448 Cl-

and ACh release, 458 and high affinity choline

uptake, 456

982

Concanavalin A, 226 Cooperativity

negative, 650 Cooper thiocholine (CuThCh)

histochemical method, 128 Cornea

ACh and choline acetyl­transferase in, 542

choline uptake in, 543 Corneal blinking

and cholinomimetics, 833 Cortex, cerebral

AChE activity in, 674 ACh output from, 690 cAMP level in, 602 cGMP level in, 602 cholineacetyltransferase in,675 cholinergic systems in, 665 muscarinic receptors in, 649 nicotinic binding sites in, 643

Cortical intrinsic cholinergic neurons, 681

Cortical cholinergic afferent pathway, 673

Crotoxin, 249 Curare-like agents, 351-365 Cyanide sodium, 420 Cyclobutonium, 356 Cyclostomes

cholinergic mechanisms in, 65 Cytochrome C oxidase, 264

D-600, 218 Deanol

see dimethylaminoethanol Decadonium, 357 Decamethonium, 360 Dementia

choline trials in, 873 Depressive illness, 947

and blood choline levels, 905 and cholinergic agents, 861

Development of cholinergic enzymes, 4

Dexetimide, 613 DFP, 290,292,847,948 Diadonium, 357 N'-N'-Dicyclohexylcarbodi-

imide, 139 Diencephalon

through phylogeny, 71

SUBJECT INDEX

Diethyl, dimethylpyrophos­phonate, 207

Diethyldithiocarbamate, 798 3,3'-Diethylthiodicarbocyanine

(diS-C2[5]), 317 Digoxin, 188 Dimethylaminoethanol, 475

(DMAE) , 437 on choline metabolism, 435

1,1-Dimethyl-3-hydroxy­piperidine, 475

3,3-Dipentyl-2,2'-oxocarbo­cyanine, 525

Diphenhydramine, 362 4-Diphenylacetyl-N-methyl­

piperidinemethiodide, 595 Diphenylcyclobutanedicarboxylic

acids, 351-365 4-Dipyrrolidino-2-butyne, 621

see tremorine Dopamine, 784,803,875

and AChE in substantia nigra,727 choline on, 429 effect on adenylate cyclase

in ganglia, 120 L-DOPA

effect on striatal ACh level, 734

Dreaming and cholinomimetics, 949

DSP-4, 784

EA0170l, 948 Eaton-Lambert syndrome

and 4-aminopyridine, 874 Echothiophate, 545 EGTA, 419,506,523,803 Electric organ, 218,238,242,

249,261,326 Electroplaque potential, 288 Electroretinography, 556 Electrostatic potential,

and choline analogs, 475 Encephalopathies,

and cholinergic disfunction,92l Endocytosis, 261 S-Endorphin, 716 Enkepha1ins, 833

effect on ganglionic transmission, 112 in adrena1s, 144

SUBJECT INDEX

Entorhina1 cortex afferents, 676 EPSP, 110, 112 Error

heteroscedastic and homoscedastic, 470

Eserine see physostigmine

Ethanol on ACh release, 188 on ACh synthesis in the iris,548

Ethanolamine, 405 Ethorphine, 149 N-Ethy1ma1eimide

and muscarinic receptor binding, 614

on ACh release, 188 Exocytosis, 495

transmitter release from vesicles, 187,261

Extensor digitorum longus, 222 Eye

cholinergic system in, 541 in cup preparation, 556

Fab, 343 False cholinergic

transmitters, 274,307,475 FCCP, 137 Feedback inhibition, 169, 782 Fenf1uramine, 781 Fimbria-fornix, 715 FLA-63, 783 Fluphenazine

on brain ACh, 455 Forebrain

GPC-diesterase, 398 Free hydroxyl group

in choline uptake, 475 Frog sartorius, 225

GABA and ACh interaction, 717,771 in hippocampus, 786 in olfactory bulb, 682 interneurons in septum, 719 on ACh release, 560,763 on neurons in the septum, 828

GABAergic agents, 715,764,773 Gallamine, 324

983

Gallamine ami.de amine inhibitor, 326

Ganglia ACh synthesis in, 97 chick ciliary development, 1 ciliary, 570 effect of black widow

venom on, 157 Ganglion of Remak in

cholinergic differenti.ation, 3 Gang1iosides, 221

and cholinergic enzymes, 841 Gilles de 1a Tourette syndrome

blood choline levels in, 910 GHa, 787

cultures of, 518 G1icera convo1uta venom, 215 Globus pa11idus

ACh output, 690 choline uptake, 685 lesion, effect on cortical

cho1ineacety1transferase, 668,685

Glucose in ACh synthesis, 416,443,491,

922 Glutamate, 875

high affinity uptake, 665 Glutamic acid decarboxylase

in the cerebral cortex, 665 Glutamine, 317 G1ycerophosphocho1ine, 395 G1ycerophosphocho1inephospho-

diesterase cations on, 399 in brain, 393 . inhibitors of, 400

Glycerol, 378 Gpp(NH)p, 611 Gramicidin D, 314 Growth medium

(eagle), 514 Guanine nuc1eotides,

and muscle receptors, 597,609 Guanylate cyclase, 601,716 5 '-Guany1y1imidodiphosphate, 597 Guinea pig

brain cortex, 308 ileum, 236,609

984

Haloperidol, 604 effect on ACh turnover, 708

on striatal ACh level, 734 HC-3

see hemicho1inium-3 Head drop, 353,354,355 Heart

ACh synthesis, 159 development in chick embryos,86 muscarinic receptors in, 590

Hemicho1inium-3, 99,135,161,170, 301,400,402,476,482,493,501,772

Hexobarbital in barbiturate abstinence, 819

Hill plot, 547 Hippocampus

ACh level in, 716,782 ACh release from, 782 ACh turnover in, 708,716,782 afferents to, 782 and septal lesions, 842 and tetrahydrocannabinol, 825 high affinity choline uptake

in, 782 innervation, 710 nicotinic receptors in, 640 slices, ACh release from, 580

Homarus americanus axons, 369 Homocho1ine, 475

uptake, 100, 102 Horseradish peroxidase, 673

transport by cholinergic neurons in the cortex, 670

5-HT and AChE, 741 see also serotonin

Huntington, George, 871 Huntington's chorea

and 4-aminopyridine, 871 and arecoline, 875 and choline therapy, 871 and neuroleptic drugs, 874 and neuronal degeneration, 875 and neurotransmitter

interactions, 875 and striatal cholinergic

liypofunction, 871 N-(40Hydroxybuty1)-M,N,N-tri­

methy1ammonium, 99,475

SUBJECT INDEX

(-)-Hydroxy citrate, 418 6-Hydroxydopamine, 711,772

effect on ACh turnover, 708 Hypoglycemia, 925 Hypothalamus, 716

nicotinic binding sites in,643 Hypoxia

histotoxic, 443,923 hypoxic, 444,923

IgG, 343 in myastenic patients, 334

Indo1eamines and cholinergic mechanisms, 739

Iodoacetate and choline uptake, 135

Ions effect on muscarinic receptors,

647 Iris

AChE inhibition in, 569 cholinergic system in, 541 development of cholinergic

innervation, 1 Isobuty1-1-methy1xanthine, 400 Isoniazid, 605

K+, 188,525 on ACh release, 580 on ACh synthesis, 531

Kainic acid, 777,787,788 and cholinergic neurons, 665

KNC and ACh synthesis, 444

Kinetic coupling between choline and

ACh synthesis, 489 Kynurenine, 756

Lacrimal glands muscarinic binding sites in,596

Lactate dehydrogenase, 264 Lantanum, 209,224,803 Learning

and cholinergic system, 859 Lecithin

and ACh synthesis, 427 effect on memory, 937

on plasma choline 1eve1s,943 see also phosphatidy1cho1ine

SUBJECT INDEX

Leptocurares, 324 Levetimide, 613 Libinia emarginata

axons, 369 Lidocaine, 372 Light

effect on ACh release, 555 Lineweaver-Burke plot, 499 Lithium

assay for, 894 blood cell/plasma ratio, 898 plasma level in therapy, 898 RBC level in therapy, 898 treatment and blood choline

levels, 910 Locus ceru1eus, 781

AChE-noradrenergic relation­ships in, 735

Lysolecithin, 256,405 Lysophosphatidy1serine, 601

Magnoce11u1ar nuclei of the substantia innominata, 673

3H-4-(N-Ma1eimido)benzyltri-methy1ammonium (MBTA), 374

Mania, 947 Marijuana, 825 Mass spectrometry, 497,532,715,827 Mebhydro1ine, 362 Mecamylamine, 803 Medulla oblongata

through phylogeny, 70 Membrane fluidity, 257 Membrane transport systems

and neurotoxins, 249 Memory

and cholinergic system, 859 and cholinomimetic agents, 929 effect of lecithin on, 937

Mepp, 223,343 Mesencephalon

through phylogeny, 71 Metabolic inhibitors

in ACh synthesis, 420 Methionine, 405 Methy1atropine, 803,833 B-Methy1choline, 803 Methy1dioxo1ane, 613 Methy1isopropy1fluorophosphate,325

985

a-Methylparatyrosine, 783,798 N-Methyl-4-piperidinylbenzi1ate

as a muscarinic ligand, 647 N-Methy1scopolamine, 591,595,950 Methy1sergide, 767 Mg++, 400,493,506,557 MIPF, 325 Mitochondria, 264,383 Mitochondrial fraction

choline incorporation in, 516 Mn++, 183 Modulatory processes, 715 Monoethy1cho1ine, 475 Morphine, 149,177,796,835 Motoneuron sprouting, 221 Motor cortex, 676 Motor disfunction

and cholinergic drugs, 856 a-MSH

on hippocampal ACh turnover,718 Muscarinic receptors

agonist of, 613 and guanine nuc1eotides, 609 and N-ethylma1eimide, 614 agonist of, 613 autoreceptors, 579 binding, 609 binding states of, 595,609 effect of ions on, 647 in chronic barbital

treatment, 809 in myenteric plexus, 169 in the eye, 541 in the iris, 571 kinetic constant of, 649 localization by radio-

histochemistry, 587 presynaptic, 169,579,784 regulation of, 609 supersensitivity, 9.50

Muscimol, 717,772 effect on ACh turnover 708 intraseptal, 827 '

Muscle AChE in, 197 and antibody localization,344 cell culture, 343 ChAT activity in, 205 ciliary, 544

986

denervated, 387,659 mammalian, skeletal, ACh

content, 205 Myasthenia gravis, 333,343,879

cholinergic drugs in, 854 Myastenic

immunoglobulins, 343 motor endp1ates, 333 serum, 333

Myenteric plexus ACh release from, 169,175 false transmitters,

uptake in, 308 muscarinic receptors in, 169 synaptic vesicles from, 235

Myocardium development in chick embryos, 85

Na+ channel, and neurotoxins, 249 on ACh release, 188 on choline uptake, 478

Naloxone, 184,796,835 4-C-1-Naphthy1viny1)­

pyridine, 212,432 Narcine brasiliensis, 241

synaptic vesicles, 314 Narcotic antagonists

and antinociception, 796,834 Neostigmine

pharmacokinetics of, 879 Neostriata1 slices, 531 Neural crest, 2,3 Neuraminidase, 518 Neuroleptic drugs

in Huntington's chorea, 874 Neuromuscular

junction, 221 preparation, 223

frog, 215,344 transmission, 223,343,353

Neuronal cultures, 511 Neuropeptides, 875

and hippocampal ACh, 715 Neurotoxins, 249 Nicotine, 372

binding in the brain, 641 Nicotinic receptors

antibody against, 333,343 composition of, 329

SUBJECT INDEX

in denervated skeletal muscle, 659

in developing electric organ, 50

interaction with opiates, 151 in the brain, 639 in the eye, 541 separation from AChE, 325 structure of, 653

Nigericin, 137,318 Nomifensine

on ACh turnover, 710 Noradrenaline, 803

and 4-aminopyridine, 874 content in hippocampus, 788 effect on ACh release, 526

on cAMP levels in gang1ia,121 in the iris, 571

Noradrenergic pathways, 681,782 Norepinephrine

see noradrenaline Notechis II-S, 249 Notexin, 249 Nucleus basalis

magnoce11u1aris, 666,673 of Maynert, 668

Obidoxim, 329 Olfactory bulb, 699 Olfactory cortex, afferents, 675 Oligomycin, 137 Opiates

action on adrenal, 148 receptors, 149

Ouabaine, 293 on ACh release, 224,580 on rubidium uptake, 522

Oxotremorine and ACh turnover, 782 and choline uptake, 782 and postsynaptic mechanism,782 and presynaptic mechanism, 169 and QNB binding, 613 antinociceptive activity,

795,833 effect on ACh release, 169,182,

580,782 on hippocampal ACh and

choline levels, 782

SUBJECT INDEX

on striatal ACh and choline levels, 734

in the eye, 545 structure-activity relation­

ships, 621 Oxygen

and ACh synthesis, 444 Oxythiamine, 288

Pachycurares, 324 Pain mechanisms, 860 Pancurone, 874,880 Paraoxon, 420,427,453,500,847 Pathways

cholinergic, 673,680,715,777, 786

dopaminergic, 777 glutamatergic, 777 noradrenergic, 681,782 peptidergic, 716 serotoninergic, 777,782

PCl2 cells, l33 Penfluridol, 783 Peptidergic septal afferents, 716 Perforant pathway, 710 PGEl

adenylate cyclase in ganglia, effect on, 120

Phenoxybenzamine, 767,783 on ACh turnover, 710

Phentolamine, 766 Phenylmethanesulfonylfluoride,324 Pheochromocytoma, 133 Phosphatidylcholine, 393,405,873 Phospholine

see echothiophate Phospholipids, 377,378,601

and choline concentration, 495 in vesicles

content, 242 turnover, 383

Phospholipon, 939 Phosphorylcholine, 437,513,873 Physostigmine

and antinociceptive activity, 795,833

and cortical arousal, 949 and dreaming, 949 and first REM period, 949 and hypoglycemia, 925

987

and memory, 933 and mouse behavior, 858 and thiamine deficiency, 925 binding to axonal

membranes, 292,372 in Huntington's chorea, 875 on ACh release on brain cAMP, 601 on brain cGMP, 601 similarity with a tryptamine

deriva tive, 756 Picrotoxin, 561,766,775 Pilocarpine, 950

and binding, 613 antinociceptive activity,

795,835 Pimozide, 783

effect on striatal ACh level, 734

Pirenzepine binding to tissues, 596,650

Placenta ChAT from, 94

Plasma choline, 871,897 Positron emitting tomography,875 Pralidoxime

and AChE reactivation, 850 Presynaptic muscarinic

receptor, 169,784 Primary affective illness

and cholinomimetics, 947 and lithium therapy, 893 REC/plasma choline, ratio in,

897 Procaine, 362,372,833 Prolactin, 717,947 Promethazine, 362 Propionylcholinesterase

(PrChE), 131 Propranolol, 783 Propylbenzilcholine, 595 Propylthiouracil

effect on ChAT and choline uptake, 78

Psychiatric diseases and blood choline, 901

Pyridostigmine pharmacokinetics of, 879

Pyrithiamine, 925

988

N-(4-Pyrro1idino-2-butynyl)-2-pyrrolidone, 621 see oxotremorine

Pyrro1idinecholine, 475 Pupillary function, 572 Pyruvate

in ACh synthesis, 415,501

Quinidine, 188,293 (±)Quinuclidinylbenzilate

(QNB), 364,372,544,584,647, 613,772

Quipazine, 787

Radiohistochemistry of muscarinic receptors, 587

Receptogenesis, 11 Receptor

binding., 575 regulation, 544

Red blood cells human, choline content, 897

Regeneration-reinnervation, 221 REM sleep, 947

and arecoline, 949 Reptiles

brain cholinergic mechanisms in, 65

Reserpine, 604,782,796 Retina

ACh release from, 555 synthesis in, 543

Rosenblueth's phenomenon, 105 Rubidium uptake, 522

Scatchard plot, 545,590 Scopolamine, 950

and mouse behavior, 858 on ACh release, 169 on binding, 613 on brain cAMP, 601 on brain cGMP, 601 on T-maze, 604

Schizophrenia and cholinergic agents, 861

Schwann cells, 369 ACh release from, 223

Seizures on cholinergic mechanisms, 809

SUBJECT INDEX

Septal-hippocampal cholinergic pathWay, 680,715

neuropeptides on, 715 Septum, 699,705

lesions, effect of gangl1.osides, 841

Serotonin, 803 in hippocampus, 788 in the striatum, 730 see also 5-HT

Serotoninergic pathways, 782 Sleep

and cholinergic drugs, 856,949 Smooth endoplasmic reticulum

and choline phosphoglyceride axonal transport, 381

Soman, 573 Somatostatin, 710 Somite, 86 Sphingomyelin, 393 Spiroperidol, 766 Storage granules, 139 Striatum

cholinergic-monoaminergic relationships in, 728

cholinergic neurons in, 670 nicotinic binding sites in,643

Substance P, 716 effect on ganglionic

transmission, 110 Substantia nigra

AChE in, 725 Succinylcholine, 360 Sulfocholine, 475 Superhigh affinity

of muscarinic receptors,590,609 Supersensitivity, 545

and chronic scopolamine, 950 Synaptic vesicles, 216

ACh content in, 294 storage in, 273 uptake into, 301

active, 274 biochemical composition,242-268 from myenteric plexus, 235 from narcine, 313 from Torpedo, 242,261,301 heterogeneity, 261

subpopulation, 274

SUBJECT INDEX

transmembrane potential, 320 turnover, 383

Synaptosomes, 239,250,447,469, 476,492

Synaptogenesis, 1

Taipoxin, 249 Tardive dyskinesia

choline trials in, 873 Tectum

through phylogeny, 70 Telencephalon

through phylogeny, 71 Te1eosts

brain cholinergic mechanisms in, 65

Tetrabenazine, 796 ~9 Tetrahydrocannabino1s

effect on ACh turnover, 826 Tetrahydroharmane

on ACh activity, 748 Tetrapheny1boron, 416 Tetradotoxin, 190,765

binding to axonal membranes,372 on ACh release, 527,580

Theophylline, 293,400 Thiamine

deficiency, 925 on ACh release, 293

Thyroid deficiency and ChAT activity, 78 and choline uptake, 78

Tolerance to barbital, 809 to scopolamine, 950

Torpedo ca1ifornica nicotinic receptors in, 241,654

Torpedo marmorata, 249 AChE from, 50

989

ACh release from, 218,238,242, 261,287,309

ChAT from, 50 developing electric organ,

electric organ discharge, 52 nicotinic receptors, 50 synaptic vesicles, 238,301,

313,326 Torpedo nobi1iana, 374 Transmitters

in the iris, 571 Tremor, 624 Tremorine, 621

antinociceptive activity, 795,833

Triethy1cho1ine, uptake, 100,475 N,N,N-Trimethy1-N-Prop-2-)

yny1ammonium, 475,476,483 [3H] Tripheny1methy1phosphonium

Br (TMTP), 314 Truxi11ic acids, 351-365 TUbercidine, 293 d-Tubocurarine, 292,336,364,370

binding sites in the brain,640 Tyrosine hydroxylase, 787

Vagus, stimulation effect on ACh release, 160

Valinomycin, 137,315 Veratridine, 523

binding to axonal membranes, 372

on ACh release, 580 on choline uptake, 493

Videotape recording of patients, 874

Withdrawal, barbital, 809